Cart
sales@molnova.com
BCL6 PROTAC 15
CAS No.
BCL6 PROTAC 15 ( —— )
Catalog No. M16949 CAS No.
BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBCL6 PROTAC 15
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines.
-
DescriptionBCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight976.48
-
Molecular FormulaC47H58ClN9O12
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name4-((R)-25-chloro-41-methyl-42-oxo-41,42,43,44-tetrahydro-5,8-dioxa-3-aza-4(6,8)-quinolina-2(2,4)-pyrimidina-1(1,2)-piperazinacyclononaphane-14-yl)-N-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)propyl)-4-oxobutanamide compound with ethane (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. McCoull W, et al. ACS Chem Biol. 2018 Oct 17. doi: 10.1021/acschembio.8b00698.
molnova catalog
related products
-
BSJ-03-123
BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader (PROTAC).
-
BM-PEG3
BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
NH2-PEG6-Boc
NH2-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG6-Boc is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
